The effects of fractional microablative CO2 laser therapy on sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy. (3rd April 2019)

• Record Type: Journal Article
• Authors: Gittens, Paul; Mullen, Gregory
• Is Part Of: Journal of cosmetic and laser therapy. Volume 21:Number 3(2019)
• Page Start: 127
• Page End: 131
• Publication Date: 2019-04-03
• Subjects: Lasers -- postmenopause -- sexual Dysfunction -- physiological -- breast Neoplams; Skin -- Laser surgery -- Periodicals; Surgery, Plastic -- Periodicals; 617.477
• DOI: 10.1080/14764172.2018.1481510
• Languages: English
• ISSNs: 1476-4172

Abstract

ABSTRACT: Purpose : To examine the outcomes of sexual function in postmenopausal women and women with a history of breast cancer treated with endocrine therapy who were experiencing the symptoms of GSM for which they were treated with fractional microablative CO2 laser.Materials and Methods : From July 2015 to October 2016, a retrospective chart review of women who underwent fractional microablative CO2 laser therapy (MonaLisa Touch, DEKA) for GSM was conducted. Several validated questionnaires were used to assess changes in symptoms and sexual function including the Female Sexual Function Index (FSFI), the Wong-Baker Faces Scale (WBFS), and the Female Sexual Distress Scale—Revised (FSDSR). Comparisons of mean symptom scores were described at baseline and six weeks after each treatment.Results : There was a statistically significant improvement in every domain of FSFI, WBFS, and FSDS-R when comparing baseline symptom scores to after treatment three symptom scores for all patients. The secondary outcome was to evaluate the differences, if any, in outcomes of sexual function between postmenopausal women and women with a history of breast cancer treated with endocrine therapy. Both groups had statistically significant improvements in many domains studied.Conclusions : Fractional microablative CO2 laser therapy (MonaLisa Touch, DEKA) is an effective modality in treating the symptoms of GSM in postmenopausal women and women with a history of breast cancer treated with endocrine therapy.